Micaela Simon
Adult Medicine · Tempe, AZNPI 1235681370
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (35.8%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Gilead accounts for 61.0% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $16,431, 6.2 times the $2,651 reported in 2021. Among adult medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 526 payments — averaging $71.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$23K
- Viiv Healthcare Company$11K
- Merck$557
- Janssen Products, LP$507
- AbbVie$361
- Johnson & Johnson$330
- plus $2K from 27 others
Across 1 payment — averaging $12,475 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$12K
What the payments were for
- Consulting fees$7,28019%
- Speaking & faculty fees$10,92829%
- Travel & lodging$5,52515%
- Food & beverage$13,45936%
- Education$3621%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 197 | $22,897 |
| Viiv Healthcare Company | 170 | $10,711 |
| Merck | 22 | $557 |
| Janssen Products, LP | 6 | $507 |
| AbbVie | 12 | $361 |
| Johnson & Johnson(2 entities) | 20 | $330 |
| EMD Serono, Inc. | 10 | $242 |
| Theratechnologies Inc. | 8 | $230 |
| Abbott | 4 | $214 |
| Novo Nordisk | 6 | $193 |
| Napo Pharmaceuticals Inc | 19 | $189 |
| Organon | 3 | $140 |
| Janssen Scientific Affairs, LLC | 1 | $119 |
| AstraZeneca | 7 | $99 |
| Pfizer | 5 | $94 |
| Hologic Sales And Service, LLC | 4 | $88 |
| Antares Pharma, Inc. | 6 | $87 |
| Lilly USA, LLC | 4 | $74 |
| Exact Sciences | 4 | $69 |
| Myriad Women's Health, Inc. | 1 | $53 |
| Amgen | 3 | $47 |
| Medtronic | 2 | $43 |
| Mayne Pharma Commercial LLC | 2 | $28 |
| Indivior Inc. | 1 | $28 |
| Nevro Corp. | 1 | $25 |
| Phadia US Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Tolmar, Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Seqirus USA Inc | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,554 in reported general payments places this provider in the 95th percentile of 35 adult medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 38 | $150,921 |
| DescovyEmtricitabine/Tenofov Alafenam | 35 | $85,000 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 11 | $1,172 |
| Rosuvastatin Calcium | 11 | $268 |
| Gabapentin | 14 | $229 |
| Doxycycline Monohydrate | 13 | $180 |
| Valsartan | 12 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $22,897 | $235,92173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 adult medicine providers in Arizona.
Other adult medicine in Tempe
- Ann KhalsaPhoenix$494K
- Jessica HoffmanTucson$6K
- Shiny ThomasMesa$4K
- Joseph RotellaScottsdale$3K
- Jean NelsonPhoenix$2K
- Vern StrubeckTucson$1K
- Jenna BolgerGlendale$1K
- Rommel Paulo MesolaBuckeye$964
- Kimberly WallsPhoenix$886
- Georgina HinesMesa$805
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.